Genetic Evidence Links GLP-1 Receptor Agonists to Reduced Stroke and Alzheimer’s Risk Across Diverse Populations
Genetic evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may protect against Alzheimer’s disease and stroke, according to a Mendelian randomisation study published in Neurology: Genetics. Researchers analysed genome-wide association study summary statistics across European, East Asian, and African ancestry groups to evaluate whether the cardiovascular and metabolic benefits of these medications extend to neurological health. The findings demonstrate protective associations for ischaemic stroke, cardioembolic stroke, and Alzheimer’s disease, though investigators emphasise that clinical trials remain necessary to confirm direct treatment benefits.
Two-Sample Mendelian Randomisation Methodology Across Multiple Ancestries
To investigate potential causal relationships between GLP-1RA effects and neurological outcomes, a two-sample Mendelian randomisation analysis utilised genetic variants as proxies. The study examined datasets from populations of European, East Asian, and African ancestry, encompassing sample sizes that ranged from 3,026 to 1,812,017 individuals. This methodological approach included participants both with and without type 2 diabetes, stroke, and Alzheimer’s disease. By leveraging genetic variation, the study aimed to generate unbiased estimates of drug target effects on brain health before experimental clinical trials.
Ancestry-Specific Findings and Cross-Ancestry Meta-Analyses
Among European participants, locus-based analyses identified protective associations with any stroke and ischaemic stroke that remained statistically significant after adjustment for multiple comparisons, with false discovery rate-adjusted values remaining below the statistical threshold. In East Asian participants, odds ratios pointed in the same protective direction for stroke at 0.81 and Alzheimer’s disease at 0.67, though neither reached statistical significance. Exploratory analyses involving participants of African ancestry similarly suggested a protective trend, but limited statistical significance restricted definitive conclusions for that specific group.
When researchers combined evidence through cross-ancestry meta-analyses, robust protective associations emerged. The pooled data yielded significant odds ratios for any stroke at 0.75, ischaemic stroke at 0.72, cardioembolic stroke at 0.55, and Alzheimer’s disease at 0.51. All four combined associations met the false discovery rate-adjusted significance threshold.
While the genetic data support further investigation of GLP-1RAs as potential therapeutic options for reducing neurological disease risk, the study authors caution that genetically proxied effects do not directly establish the clinical efficacy of prescribing these medicines. Lead researchers state that experimental studies and formal clinical trials are required to confirm whether active treatment provides real-world protection and to clarify the biological mechanisms underlying the observed associations.
Frequently Asked Questions About GLP-1RAs and Neurological Health
What specific types of stroke showed protective associations in the study?
Cross-ancestry meta-analyses identified protective associations for any stroke, ischaemic stroke, and cardioembolic stroke, with odds ratios reaching 0.75, 0.72, and 0.55 respectively.
Which ancestry groups were included in the Mendelian randomisation analysis?
The research analysed datasets from populations of European, East Asian, and African ancestry, utilizing summary statistics from genome-wide association studies.
What peer-reviewed journal published these findings?
The study was published in Neurology: Genetics in 2026 by lead author I. Caro-Châtelier and colleagues under the title Genetic insights into protective effects of GLP-1 receptor agonists on stroke and alzheimer disease across ancestries.
Related reading